Search results | celgene

Reports

Partnering Agreements with Celgene

This report provides all the information you require to better understand Celgene and its partnering interests and activities over the past seven years.

Insights

Celgene

Celgene is a top pharmaceutical company, incorporated in Delaware and headquartered in Summit, New Jersey

Celgene; Going ‘green’ for transformative technologies

Celgene is a big pharmaceutical company discovering and developing medical treatments indicated for cancer and other inflammatory conditions.

Celgene: M&A activity 2005-2013

Celgene has announced over 6 M&A deals since 2005, with the lead deals being the acquisition of decode Abraxis and Pharmion

Celgene: Partnering activity 2005-2013

Celgene announced over 43 partnering / licensing deals since 2005

Celgene: Company Profile

Celgene, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Big Pharma Celgene pharma alliances with PharmAria to advance small molecule therapeutics

Celgene Corporation, a top 50 pharma company has entered into  strategic pharma alliances agreement with PharmAria to advance the discovery of new high quality small-molecule therapeutics targeting cancer and fibrotic diseases

VentiRx Pharma inks pharma partnering deal with Celgene for cancer drug VTX-2337

VentiRx Pharmaceuticals announced the formation of an exclusive, world-wide pharma partnering collaboration with Celgene Corporation for the development of VTX-2337, a highly potent and selective TLR8 agonist for the treatment of cancer.

Is big biotech Celgene bidding for Human Genome Sciences?

Celgene, a big biotech/pharma company is not buying Human Genome Sciences, according to a source in contact with Celgene management

Dealmakers weekly review – July 3 2012 – Amylin, Bristol-Myers Squibb, AstraZeneca, Biogen Idec, Celgene, Inhibrx

BMS acquires Amylin and then collabroates with AstraZeneca on diabetes franchise dominates the weeks dealmaking

Dealmakers weekly review – January 30 2012 – Roche, Illumina, Amgen, Micromet, Celgene, Avila, Boehringer Ingelheim, Priaxon

Three mega M&A announcements and a slowing of partnering activity

Events

Sorry, your search returned no results.


Deals

Celgene acquires Quanticel Pharmaceuticals

Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel

Celgene and AstraZeneca in MEDI4736 pact

Celgene has entered into a strategic collaboration with MedImmune to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies

Mesoblast banks $45mn financing from Celgene

Mesoblast has entered into an Agreement with Celgene

Morphosys regains MOR202 rights from Celgene

MorphoSys has regained rights to MOR202 from Celgene

Celgene and Open Monoclonal Tech in OmniAb alliance

Open Monoclonal Technology announced license that provides Celgene with unlimited access to OMT’s proprietary OmniRat, OmniMouse and OmniFlic platforms for generation of human antibody therapeutics

Celgene and Zymeworks partner for bi-specific antibody therapeutics

Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform

Celgene licenses AG-120 from Agios

Agios Pharmaceuticals announced that its collaboration partner Celgene has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120

Triphase and Celgene announce a pharma deal for bi-specific antibodies

Triphase Accelerator announced a new strategic pharma deal with Celgene.

Sutro and Celgene sign a pharma deal for $1 billion

Sutro Biopharma has entered a pharma deal and option agreement with Celgene to discover and develop antibodies and antibody drug conjugates.

BMS and Celgene become pharma partners for evaluating cancer drugs

Bristol-Myers Squibb and Celgene become a pharma partners for evaluating the efficacy of combination treatment using  OPDIVO and ABRAXANE.